Drug
Smoflipid
Smoflipid: highest development phase Post-Market, developed by Fresenius Kabi. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| SMOFlipid® (lipid injectable emulsion) NCT06049680 | Post-Market | Malnutrition, Child |
Latest
No recent events.
Follow Smoflipid on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.